Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/37517099http://www.w3.org/2000/01/rdf-schema#comment"

Background

Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers. Recently, pyrroline-5-carboxylate reductase 1 (PYCR1) and proline metabolism have been reported regulatory roles in the anti-tumor response.

Methods

There were three cohorts enrolled: two from our institution (ZS-MRCC and ZS-HRRCC) and one from a clinical trial (JAVELIN-101). The PYCR1expression in each sample was evaluated by RNA sequencing. Flow cytometry and immunohistochemistry were performed to assess immune infiltration. Single-cell RNA-seq (scRNA-seq) data was used for cluster analysis of T cells and macrophages. Primary endpoints were set as response and progression-free survival (PFS).

Results

Patients in the low-PYCR1 group had greater objective response rate (52.2% vs 18.2%) and longer PFS in both cohorts (ZS-MRCC cohort, P=0.01, HR=2.80; JAVELIN-101 cohort, P<0.001, HR=1.85). In responders, PYCR1 expression was decreased (P<0.05). In the high PYCR1 group, CD8+ T cells exhibited an exhausted phenotype with decreased GZMB (Spearman's ρ=-0.36, P=0.02). scRNA-seq revealed tissue-resident memory T (Trm) (P<0.05) and tissue-resident macrophage (P<0.01) were decreased in samples with high PYCR1 expression. A machine learning score was further built by random forest, involving PYCR1 and Trm markers. Only in the subgroup with the lower RFscore did IO+TKI show a favorable outcome, compared to TKI monotherapy.

Conclusions

Immunosuppression and IO+TKI resistance were correlated with high PYCR1 expression. T cell exhaustion and dysfunction were also related with the expression of PYCR1. PYCR1 has the potential to be employed as a biomarker to discriminate between IO+TKI and TKI monotherapy as the optimal patient treatment strategy."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.org/dc/terms/identifier"doi:10.1016/j.neo.2023.100919"xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Guo J."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Hu X."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Wang Y."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Wang J."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Xu X."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/author"Zhu Y."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/date"2023"xsd:gYear
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/name"Neoplasia"xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/pages"100919"xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/title"Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients."xsd:string
http://purl.uniprot.org/citations/37517099http://purl.uniprot.org/core/volume"43"xsd:string
http://purl.uniprot.org/citations/37517099http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/37517099
http://purl.uniprot.org/citations/37517099http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/37517099
http://purl.uniprot.org/uniprot/#_A0A1B2JLU7-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_E7D7X9-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_E7D7Y0-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_B7Z8T1-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_D6QXZ5-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_J3QL32-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_E2QRB3-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_Q2TU78-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
http://purl.uniprot.org/uniprot/#_P32322-mappedCitation-37517099http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37517099
▶